CAMP4 Therapeutics (CAMP) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

CAMP · Stock Price

USD 4.34+2.21 (+103.76%)

Market Cap: $212.4M

Historical price data

Market Cap: $212.4MPipeline: 1 drugHQ: Cambridge, United States

Sector Ranking#20 in RNA Therapeutics (non-mRNA)#51 in Neuroscience & CNS

Overview

CAMP4 Therapeutics is a clinical-stage biotech company developing first-in-class antisense oligonucleotide (ASO) therapeutics that upregulate gene expression by targeting regulatory RNA. The company has established a proprietary RAP Platform® to map gene-regulatory circuits and has advanced its lead program, CMP-001 for urea cycle disorders, into Phase 1/2 clinical development. CAMP4's strategy leverages its platform to build a pipeline in CNS and metabolic diseases while seeking strategic partnerships to expand its reach. The company is publicly traded and led by a team with deep expertise in RNA biology, drug development, and corporate strategy.

Central Nervous System (CNS)Metabolic Diseases

Technology Platform

The RAP (Regulatory RNA Atlas and Platform) Platform® systematically maps the network of non-coding regulatory RNAs that control gene expression in disease-relevant cells to identify targets for antisense oligonucleotide (ASO) therapeutics designed to upregulate specific proteins.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
CMP-CPS-001	Healthy Volunteers	Phase 1

Funding History

1

Total raised:$100M

Series A$100MUndisclosedAug 1, 2022

Opportunities

CAMP4's platform addresses a vast, untapped class of over 1,000 haploinsufficiency diseases with high unmet need.

Successful clinical validation of its lead program could unlock significant partnership potential across multiple therapeutic areas and establish a new therapeutic modality.

Risk Factors

The core technology of upregulating genes via regulatory RNA is unproven in humans, representing high clinical and biological risk.

As a pre-revenue company, CAMP4 faces significant financial risk and likely future dilution, and its value is heavily concentrated in its early-stage pipeline.

Competitive Landscape

CAMP4 occupies a unique niche focused on gene upregulation, differentiating it from ASO leaders who primarily knockdown genes and from gene therapy companies that modify DNA. Its main competition comes from alternative therapeutic strategies for haploinsufficiency, such as protein replacement or gene addition.